<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292342</url>
  </required_header>
  <id_info>
    <org_study_id>EpicatechinStudy</org_study_id>
    <nct_id>NCT02292342</nct_id>
  </id_info>
  <brief_title>An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men</brief_title>
  <official_title>An Acute, Double-blind, Randomised, Placebo-controlled, Crossover Intervention Trial Investigating the Dose-dependent Vascular Effects of Pure (-)-Epicatechin (≤1 mg/kg BW) in Healthy Men.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Reading</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To investigate the dose-dependent vascular effect (primarily using FMD) of 3 low-level
      doses of pure (-)-epicatechin ≤ 1 mg/kg BW (0.1, 0.5 &amp; 1.0 mg/kg BW) in healthy men.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow mediated dilatation</measure>
    <time_frame>baseline to 2h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laser Doppler Imaging with Iontophoresis</measure>
    <time_frame>baseline to 2h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma (-)-epicatechin metabolites</measure>
    <time_frame>baseline to 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma nitrate/nitrite</measure>
    <time_frame>baseline to 2h</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Vasodilation</condition>
  <arm_group>
    <arm_group_label>0.1 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water only (3 ml/kg BW)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Control</description>
    <arm_group_label>0.1 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>0.5 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>1.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>0.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Epicatechin 0.1 mg/kg</intervention_name>
    <description>EC 0.1 mg/kg</description>
    <arm_group_label>0.1 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>0.5 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>1.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>0.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Epicatechin 0.5 mg/kg</intervention_name>
    <description>EC 0.5</description>
    <arm_group_label>0.1 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>0.5 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>1.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>0.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Epicatechin 1.0 mg/kg</intervention_name>
    <description>EC 1.0</description>
    <arm_group_label>0.1 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>0.5 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>1.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
    <arm_group_label>0.0 mg/ kg BW pure (-)-epicatechin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index 20-27.5 kg/m2

          -  Normal blood pressure at screening (&lt; 150/90)

          -  Non-smoker

          -  Non-vegetarian

          -  'Normal - low' chocolate consumer (&lt;2 potions per week)

          -  'Normal - low' coffee/ tea drinker (&lt;3 cups per day)

          -  Regular exercise routine

          -  Signed consent form

        Exclusion Criteria:

          -  Haemoglobin (anaemia marker) &lt; 125 g/l

          -  Gamma GT (liver enzymes) &gt; 80 IU/l

          -  Cholesterol &gt; 6.5 mmol/l

          -  Suffered a myocardial infarction or stroke in the last 12 months

          -  Suffers from any cardiovascular or metabolic disorders (e.g. diabetes or any other
             endocrine or liver diseases)

          -  Suffers from any blood-clotting disorder, and/or takes supporting medication

          -  Any dietary restrictions or on a weight reducing diet

          -  On any lipid-modifying or blood pressure lowering medication

          -  Consuming any specific vitamin/ herbal supplements or fish oils
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Spencer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Reading</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Food and Nutritional Sciences</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG6 6AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Reading</investigator_affiliation>
    <investigator_full_name>Jeremy Paul Edward Spencer</investigator_full_name>
    <investigator_title>Professor Jeremy P.E. Spencer</investigator_title>
  </responsible_party>
  <keyword>Flow mediated dilatation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

